+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 22Years - 75Years
All Genders
ID06559891

THRIVE Study Evaluating the TIVUS Renal Denervation System Compared to Sham Procedure for Adjunctive Treatment of Hypertension

Led by SoniVie Inc. · Updated on 2026-09-24

261

Participants Needed

51

Research Sites

71 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the TIVUS Renal Denervation System for people with hypertension, focusing on its safety and additional effects when used alongside or instead of antihypertensive medications. The study includes adults aged 22 to 75 who have uncontrolled or controlled high blood pressure and are willing to stop their blood pressure medications for a specified period around the procedure. This international, randomized, double-blind, sham-controlled trial aims to compare TIVUS with a minimally invasive sham procedure to better understand its role in managing hypertension. Participants undergo a renal artery catheterization where the TIVUS device uses ultrasound energy to target nerves around the renal arteries. Those randomized to the sham group receive an angiogram serving as a placebo procedure. All subjects stop their antihypertensive drugs for a 4-week washout before and 2 months after the procedure. After 2 months, participants with uncontrolled hypertension restart medications following a set protocol. Some patients in the sham group with uncontrolled blood pressure at 6 months may choose to receive the TIVUS treatment. Follow-up for those treated with TIVUS lasts up to 36 months. During the study, participants will have regular blood pressure measurements taken through ambulatory, home, and office monitoring. Researchers will assess daytime and 24-hour blood pressure changes from before treatment to 2 months post-procedure, as well as track major adverse events up to 6 months. The study will also monitor blood pressure targets, reductions at various time points, and safety outcomes. Participants are evaluated at scheduled visits for up to three years to understand the long-term effects and safety of the TIVUS system.

CONDITIONS

Brief Title

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

Research Team

L

Lisa Melchior

J

Janelle Noble

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here